FDA Grants Priority Review to Eribulin for Soft-Tissue Sarcoma


The US Food and Drug Administration has granted a Priority Review designation to eribulin for the treatment of inoperable soft-tissue sarcoma.

Eribulin is under review for the treatment of leiomyosarcoma and liposarcoma.

The US Food and Drug Administration (FDA) granted a Priority Review designation to eribulin for the treatment of inoperable soft-tissue sarcoma. The application is specifically for patients who have received prior chemotherapy for advanced or metastatic disease.

“Advanced soft-tissue sarcoma is very difficult to treat, so we are excited to be one step closer to potentially bringing an additional treatment option to patients in need,” said Kenichi Nomoto, PhD, president of Eisai’s Oncology Product Creation Unit, in a press release.

The new drug application submitted to the FDA for eribulin is specifically for patients with advanced leiomyosarcoma and liposarcoma. Eribulin is a microtubule dynamics inhibitor, the first agent in what is known as the halichondrin class. It is currently approved for patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens-specifically an anthracycline and a taxane in either the adjuvant or metastatic setting.

The drug is still being investigated in sarcoma patients. Results of one phase II study were published in 2011 in Lancet Oncology, and showed promising outcomes. Of 38 leiomyosarcoma patients who received eribulin, 31.6% were progression free at 12 weeks. Also, 46.9% of adipocytic sarcoma patients, 21.1% of synovial sarcoma patients, and 19.2% of other types of sarcoma patients were progression free at 12 weeks.

The most common adverse events in that phase II study included neutropenia, leucopenia, anemia, and fatigue.

A phase III study is currently ongoing testing eribulin’s efficacy in advanced soft-tissue sarcoma patients who received at least two prior standard treatment regimens. The study is expected to include about 450 patients, and has an estimated completion data of February 2016.

The Priority Review granted to eribulin means the FDA has set a goal to take action on the application within 6 months. The standard review period is 10 months.

Related Videos
The difference in adverse effect profiles between sorafenib and nirogacestat may make one treatment more appealing than the other for certain patients with desmoid tumors, says Brian Van Tine, MD, PhD.
The August CancerNetwork Snap Recap takes a look back at key FDA news updates, as well as expert perspectives on the chemotherapy shortage.
Future developments in the sarcoma space may also involve research on circulating tumor DNA and metabolic therapies, according to Brian Van Tine, MD, PhD.
Current research in the sarcoma space includes the development of treatment options such as T-cell therapies, and combinations such as TKIs/immunotherapy, according to Brian Van Tine, MD, PhD.
Brian Van Tine, MD, PhD, states that sitravatinib appears to be active and well tolerated among patients with dedifferentiated or well-differentiated liposarcoma.
Brian Van Tine, MD, PhD, also discusses how the treatment of desmoid tumors has evolved following data supporting the use of sorafenib in this population.
CAR T-cell therapies and immunotherapy agents may offer up new options and even become standard of care in certain sarcoma subtypes.
There are several novel treatments that may be beneficial in several sarcoma subtypes including CAR T-cell therapies and immune checkpoint inhibitors, according to Sandra P. D’Angelo, MD.
Data from a ctDNA analysis of the phase 3 INTRIGUE study indicate that KIT mutational status may be associated with response to certain Tyrosine kinase inhibitors in GIST, according to an expert from the Yale Cancer Center in New Haven, Massachusetts.
Related Content